Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- At Long Last, A Win Against Lupus: HGSI Succeeds in Phase III
- Lupus is like the Black Knight in Monty Python and the Holy Grail: it’s been telling drug developers for decades that “none shall pass†-- and when they insist on trying to cross that Phase III bridge, well, then they must die. Until this week, when Human Genome Sciences came...
- Blog posts 2009-07-22
Additional Resources
- Human Genome, Glaxo Lupus Drug Works in 2nd Trial
- By Toni Clarke and Ben HirschlerBOSTON/LONDON (Reuters) - Human Genome Sciences Inc said its experimental lupus drug Benlysta was successful in a second large clinical trial, paving the way for approval of the first new treatment for the disease in 50 years.Shares in Human Genome jumped 40 percent in pre-market...
- News items 2009-11-02
- Lupus Organizations Co-Sponsor Landmark Meeting; Outcomes to Inform FDA Guidelines for Drug Development in Lupus
- ROCKVILLE, Md., April 1 /U.S. Newswire/ -- Today, four national lupus organizations -- the Alliance for Lupus Research, the Lupus Foundation of America LFA, the Lupus Research Institute, and Rheuminations, Inc. -- co-sponsored a milestone meeting on behROCKVILLE, Md., April 1 /U.S. Newswire/ -- Today, four national lupus organizations --...
- Research articles 2003-04-01
- BREAKING NEWS: Groundbreaking lupus drug promising in second Phase III
- Human Genome Sciences and its partner GlaxoSmithKline revealed that the high dose of their experimental lupus therapy demonstrated a statistically superior response compared to placebo in a second late-stage trial, laying the groundwork for an FDA marketing application. Benlysta has helped transform HGS's prospects, and analysts were quick to...
- News items 2009-11-02
- New Orange Lupus Awareness Wristband Supports 'Life Without Lupus'
- NEW YORK, Dec. 16 /U.S. Newswire/ -- A new bright orange wristband has joined the yellow and pink cause bracelets as the latest disease awareness product-designed to promote Life Without Lupus. Lupus is an autoimmune disorder in which the body's immune sNEW YORK, Dec. 16 /U.S. Newswire/ -- A...
- Research articles 2004-12-16
- Lupus Sufferers Seek Federal Support for Public and Professional Education, Other Programs
- ROCKVILLE, Md., May 6 /U.S. Newswire/ -- More than 150 lupus patients and members of their families from across the nation will meet with members of Congress as part of the Lupus Foundation of America LFA Fifth Annual Advocacy Day on Wednesday, May 7. AROCKVILLE, Md., May 6 /U.S. Newswire/...
- Research articles 2003-05-06
- Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
- SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. -- Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) announced today that a Phase II/III study of Rituxan([R])rituximab for systemic lupus erythematosus (SLE, commonly called lupus) did not meet its primary endpoint defined as the proportion of Rituxan treated patients who achieved a...
- Research articles 2008-04-29
- OMRF scientists present papers at International Congress on Lupus in
- A pair of physician-scientists from the Oklahoma Medical Research Foundation presented papers at the 8th annual International Congress on Lupus in Shanghai, China, last week. OMRF's Joan Merrill, M.D., and John Harley, M.D., Ph.D., each gave invited presentations at the four-day conference, which focuses on the autoimmune disease...
- Research articles 2007-05-30
- Heart Disease and Lupus Present Double Health Threat to Women of Color; Educational Panel Addresses Issue at Conference
- News Advisory: The Lupus Research Institute LRI National Coalition is joining with the Association of Black Cardiologists, Inc. ABC in educating attendees at the 35th Congressional Black Caucus Annual Legislative Conference about a serious health risk to women of color: heart disease in those with the chronic autoimmune disease, lupus....
- Research articles 2005-09-23
- London Investment Vehicle Lupus Has Big Appetite.
- Daily Mail, London Knight Ridder/Tribune Business News Mar. 31--Greg Hutchings, former boss of engineer Tomkins, promises to return to the FTSE 100 with his new vehicle Lupus Capital. The Lupus chairman says: "Where Tomkins was -- that is where we want...
- Research articles 2004-03-31
- Rockville-based Human Genome Sciences has positive results for lupus
- Human Genome Sciences Inc., of Rockville, a drug development company primarily focused on protein and antibody drugs, reported positive results after a clinical trial period was extended for an experimental drug to treat a chronic, life-threatening form of lupus. The share of patients responding to treatment with the drug, LymphoStat-B,...
- Research articles 2006-11-15
- La Jolla Enters Strategic Alliance Abbott for Lupus Drug
- LA JOLLA PHARMACEUTICAL Company, San Diego, Calif., has established a strategic alliance with Abbott Laboratories for the worldwide development and marketing of LJP 394, LJP's compound for the treatment of Lupus. The two companies will jointly develo LA JOLLA PHARMACEUTICAL Company, San Diego, Calif., has established...
- Research articles 1996-12-30
- Argos Therapeutics Receives $1.0 Million Grant for Lupus Research; ALR Funding to Support Antibody Research
- DURHAM, N.C. -- The Alliance for Lupus Research ALR has awarded a $1 million grant to Argos Therapeutics for development of a therapeutic antibody product for systemic lupus erythematosis SLE based on research conducted at Baylor Institute for Immunology Research. A pioneer in immunotherapy, Argos uses its expertise in dendritic...
- Research articles 2005-02-02
- Living with LUPUS/Symptoms vary widely, but fatigue is a constant
- Lupus is a disease with many faces. In one person, it might bring on a rash. In another, it might cause joint pain. It's an ailment whose symptoms can be as varied as the people who get it. "Everybody's different," says Sara...
- Research articles 2000-09-12
- U.S. HHS: New NIAMS-funded "SCORs" focus on lupus.
- M2 PRESSWIRE-13 August 1998-U.S. HHS: New NIAMS-funded "SCORs" focus on lupus C1994-98 M2 COMMUNICATIONS LTD RDATE:120898 Two new specialized centers of research SCORs have just been funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS as part...
- Research articles 1998-08-13
- Yale researchers shed light on B cells' involvement in autoimmune diseases like lupus.
- M2 PRESSWIRE-25 September 2002-YALE UNIVERSITY: Yale researchers shed light on B cells' involvement in autoimmune diseases like lupus C1994-2002 M2 COMMUNICATIONS LTD RDATE:09252002 New Haven, Conn. -- Using genetically altered mice, Yale researchers have generated a clearer picture of...
- Research articles 2002-09-25
- Six more genes linked with autoimmune disease lupus
- PARIS AFP — Investigators reported on Sunday they had identified six more gene regions associated with the severest form of lupus, a complex autoimmune disease that mainly strikes women. Lupus causes human antibodies -- the frontline troops in the defence system -- to attack the body's tissues, resulting in...
- Research articles 2008-01-20
- SensiGen Options Epigenetic Biomarkers for Early Detection and Monitoring of Lupus
- ANN ARBOR, Mich. & PHILADELPHIA -- SensiGen LLC, a biotechnology company developing advanced gene-based molecular diagnostics, announced today that it has acquired an option from the University of Michigan to exclusively license a set of epigenetic biomarkers for early detection and monitoring of Lupus. The technology includes a patented panel...
- Research articles 2007-07-11
- Doctor wins lupus funding
- Dr. Brian L Kotzin of the University of Colorado at Denver was awarded $500,000 by the Alliance for Lupus Research to further his investigations into the cause of lupus, an autoimmune disease in which antibodies attack the kidneys and other organs.
- Research articles 2003-05-01
- Hutchings returns to City with 12% of Lupus
- GREG HUTCHINGS, the former chief executive of Tomkins, said yesterday that he is investing pounds 2.1m in return for a 12 per cent shareholding in a listed company that aims to acquire troubled industrial groups. Mr Hutchings, 56, will become executive chairman of Lupus Capital. He and...
- Research articles 2004-01-17
- << Previous
- page 1 of 1
- Next >>
